TCT 2016: Structural heart, drug-coated balloons take their turn on Day 3

The annual Transcatheter Cardiovascular Therapeutics conference is under way in Washington, D.C., with late-breaking study results beginning Oct. 29. We’ll update this post throughout the day as new results come in, so be sure to check back for the latest news out of TCT 2016. After stents took center stage Day 1, with a raft of studies covering the latest on the bioresorbable front, transcatheter valve replacements were the focus on Day 2. Day 3 saw a wider variety of topics, featuring big-name devices for structural heart repair and peripheral artery disease at the Transcatheter Cardiovascular Therapies conference: Stellarex drug-coated balloon from Spectranetics bests PTA at 1 year The Stellarex drug-coated balloon made by Spectranetics (NSDQ:SPNC) beat out percutaneous transluminal angioplasty in the 300-patient Illumenate pivotal study reported today at the meeting. The study followed a complex group of patients over 12 months to evaluate the low-dose balloon’s efficacy and safety. Nearly 50% of the patient population had diabetes, 43.9% had high rates of severe calcification, 45% suffered from cardiovascular disease, and 18% had renal insufficiency. The primary safety endpoint was a composite of freedom from device- and procedure-related death at 30 days and freedom from target limb major amputation and clinically driven target lesion revascularization; the primary efficacy endpoint was a composite of primary patency, freedom from restenosis and clinically-dr...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Balloons TCT 2016 Transcatheter Cardiovascular Therapeutics symposium (TCT) Source Type: news